6.
Tse C, Hunt M, Brown L, Lewis J
. Inflammatory Bowel Diseases-related Disability: Risk Factors, Outcomes, and Interventions. Inflamm Bowel Dis. 2023; 30(3):501-507.
DOI: 10.1093/ibd/izad182.
View
7.
Ahmed W, Galati J, Kumar A, Christos P, Longman R, Lukin D
. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021; 20(3):e361-e379.
DOI: 10.1016/j.cgh.2021.03.034.
View
8.
Zurba Y, Gros B, Shehab M
. Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review. Biomedicines. 2023; 11(3).
PMC: 10045261.
DOI: 10.3390/biomedicines11030747.
View
9.
Vernero M, Saibeni S, Scalvini D, Cicalini C, Chiarello L, Nardi S
. Prevalence and Clinical Impact of Immune-Mediated Inflammatory Diseases in Patients with Inflammatory Bowel Disease: Results from a Large Retrospective Observational Study. J Clin Med. 2024; 13(4).
PMC: 10889244.
DOI: 10.3390/jcm13041019.
View
10.
Colombel J, Ungaro R, Sands B, Siegel C, Wolf D, Valentine J
. Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER). Clin Gastroenterol Hepatol. 2023; 22(7):1487-1496.e12.
DOI: 10.1016/j.cgh.2023.09.010.
View
11.
Bezzio C, Brinch D, Ribaldone D, Cappello M, Ruzzon N, Vernero M
. Prevalence, Risk Factors and Association with Clinical Outcomes of Malnutrition and Sarcopenia in Inflammatory Bowel Disease: A Prospective Study. Nutrients. 2024; 16(23).
PMC: 11643262.
DOI: 10.3390/nu16233983.
View
12.
Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C
. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2024; 18(10):1531-1555.
DOI: 10.1093/ecco-jcc/jjae091.
View
13.
Sands B, Kozarek R, Spainhour J, Barish C, Becker S, Goldberg L
. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007; 13(1):2-11.
DOI: 10.1002/ibd.20014.
View
14.
Neurath M, Vieth M
. Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing. Gut. 2023; 72(11):2164-2183.
DOI: 10.1136/gutjnl-2023-329964.
View
15.
Zhu M, Feng Q, Xu X, Qiao Y, Cui Z, Yan Y
. Efficacy of early intervention on the bowel damage and intestinal surgery of Crohn's disease, based on the Lémann index. BMC Gastroenterol. 2020; 20(1):421.
PMC: 7733289.
DOI: 10.1186/s12876-020-01575-7.
View
16.
Solitano V, Yuan Y, Singh S, Ma C, Nardone O, Fiorino G
. Efficacy and safety of Advanced Combination Treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials. J Autoimmun. 2024; 149:103331.
DOI: 10.1016/j.jaut.2024.103331.
View
17.
Sands B, Danese S, Chapman J, Gurjar K, Grieve S, Thakur D
. Mucosal and Transmural Healing and Long-term Outcomes in Crohn's Disease. Inflamm Bowel Dis. 2024; 31(3):857-877.
PMC: 11879194.
DOI: 10.1093/ibd/izae159.
View
18.
Baumgart D, Le Berre C
. Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. N Engl J Med. 2021; 385(14):1302-1315.
DOI: 10.1056/NEJMra1907607.
View
19.
Cornet N, Aboubakr A, Ahmed W, Battat R
. Combined Advanced Targeted Therapy in Inflammatory Bowel Diseases: An Extensive Update. Inflamm Bowel Dis. 2024; .
DOI: 10.1093/ibd/izae189.
View
20.
Alsoud D, Verstockt B, Fiocchi C, Vermeire S
. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021; 6(7):589-595.
DOI: 10.1016/S2468-1253(21)00065-0.
View